AACR 2023 | The role of perioperative treatment in GC/GEJC

Yongqian Shu, MD, PhD, Nanjing Medical University, Nanjing, China, comments on recent trials assessing the role of neoadjuvant chemotherapy and immunotherapy in managing gastric or gastroesophageal junction cancer (GC/GEJC). The Phase III RESOLVE trial (NCT01534546), which assessed perioperative S-1 and oxaliplatin (SOX), and the FLOT4 trial (NCT01216644) of FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) have demonstrated the benefits of perioperative chemotherapy in this group of patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.